Table 1.
Clinical and pathological characteristics of the MTC patients.
| Modeling Group (%) (n = 1389) | Internal Validation Group (%) (n = 592) | External Validation Group (%) (n = 85) | |
|---|---|---|---|
| Age (Years) | |||
| <40 | 282 (20.3) | 100 (16.9) | 20 (23.5) |
| 40–59 | 545 (39.2) | 263 (44.4) | 47 (55.3) |
| ≥60 | 562 (40.5) | 229 (38.7) | 18 (21.2) |
| Sex | |||
| Female | 832 (59.9) | 351 (59.3) | 52 (61.2) |
| Male | 557 (40.1) | 241 (40.7) | 33 (38.8) |
| Race | |||
| White | 1178 (84.8) | 514 (86.8) | 0 (0) |
| Black | 129 (9.3) | 38 (6.4) | 0 (0) |
| Asian or Pacific Islander | 77 (5.5) | 34 (5.7) | 85 (0) |
| American Indian/Alaska Native | 5 (0.4) | 6 (1.0) | 0 (0) |
| Tumor Size (mm) | |||
| ≤20 | 736 (53.0) | 290 (49.0) | 54 (63.5) |
| 20–40 | 392 (28.2) | 172 (29.1) | 23 (27.1) |
| ≥40 | 261 (18.8) | 130 (21.9) | 8 (9.4) |
| Stage | |||
| I | 542 (39.0) | 210 (35.5) | 24 (28.2) |
| II | 291 (21.0) | 135 (22.8) | 11 (12.9) |
| III | 140 (10.1) | 66 (11.1) | 18 (21.2) |
| IV | 416 (29.9) | 181 (30.6) | 32 (37.6) |
| T Stage | |||
| T1 | 672 (48.4) | 257 (43.4) | 49 (57.6) |
| T2 | 323 (23.3) | 165 (27.9) | 25 (29.4) |
| T3 | 284 (20.4) | 122 (20.6) | 5 (5.9) |
| T4 | 110 (7.9) | 48 (8.1) | 6 (7.1) |
| N Stage | |||
| N0 | 857 (61.7) | 359 (60.6) | 35 (41.2) |
| N1a | 166 (12.0) | 77 (13.0) | 18 (21.2) |
| N1b | 366 (26.3) | 156 (26.4) | 32 (37.6) |
| M Stage | |||
| M0 | 1297 (93.4) | 547 (92.4) | 77 (90.6) |
| M1 | 92 (6.6) | 45 (7.6) | 8 (9.4) |